nShift: Belgian Companies Must Act Fast to Meet Minimum Delivery Options Requirements
Following the introduction of new legislation, nShift is offering a time-limited 25% off promotion for new customers in Belgium
Belgium’s online retailers have just 16 days to comply with a new legal requirement to provide their customers with greater delivery choice. New legislation demands that from 21 September, webshops and ecommerce retailers in Belgium must provide at least two methods for the delivery of products to consumers. Retailers will be free to choose the delivery method but (at least) one of the options is encouraged to be eco-friendly.
It’s why nShift, the global leader in experience and delivery management (DMXM) is introducing a new and limited time offer designed to help retailers comply with the new law and offer a better customer experience. New customers in Belgium will receive 25% off a subscription to any of nShift’s solutions for six months.
Sean-Sherwin Smith, Product Director, Post Purchase at nShift said, “The new law marks a major shift in how online retailers will operate across Belgium. The new rule emphasizes sustainability and customer convenience. It marks a significant change in the regulatory landscape and means multi-carrier capability must be central to how retailers operate in the future.
"Sustainability is a core part of nShift’s offer. Our 1000+ carrier library features numerous sustainable last-mile solutions. Our Checkout functionality makes it easier to quickly badge and label more sustainable delivery options so shoppers can quickly find what they are looking for.”
Multi-carrier capability
Retailers will be able to respond to these changes more easily and efficiently if they work with a delivery management partner that offers multi-carrier capabilities. Beyond meeting the new legal requirement, working with a variety of carriers means retailers can offer real choice to shoppers, gain the agility to adapt to shifting consumer demand, and grow their business. Multi-carrier deliveries enable retailers to:
- Offer a range of delivery options - shoppers expect to find the shipping solution they seek
- Boost delivery capacity - making it easier to respond to increased demand
- Improve delivery quality and efficiency – by gaining real data about the performance of each carrier
- Grow beyond borders - shipping internationally requires relationships with carrier companies that serve the relevant territories
- Build the brand and remarket to customers – by taking control of customer communications
Multi-carrier capability is at the heart of nShift’s DMXM suite of solutions. It provides enterprise-grade delivery management with a library of 1000+ ready-made carrier connections. nShift can connect retailers and consumers to over one million PUDO (pick up / drop off) locations. Retailers can automate the carrier-booking and label-printing process. This helps retailers send out more parcels, work with more carriers, and tightly control the delivery experience.
Sherwin-Smith concluded, “Businesses affected by the new law need to act fast but it’s also important they make the necessary adjustments in a scalable and sensible way. They must work with a partner that offers choice and convenience, particularly when it comes to eco-friendly carriers and emissions tracking capabilities.”
For more information on the offer or to find out how nShift could help your business with its multi-carrier offering, please visit our website, www.nshift.com.
About nShift
nShift’s delivery & experience management platform drives ecommerce success. Grow beyond limits with constant innovation and the world’s largest carrier network. Build customer loyalty with end-to-end tools that enhance experience. Unify data into usable insight that connects and optimizes processes. With nShift, make delivery the essential link between your brand and your customers.
nShift. Worry less. Ship smarter. www.nshift.com
Notes to editors
Under Article VI.45/2 of the Code of Economic Law, webshops will be required to offer at least two delivery methods, including one that is eco-friendly.
This offer is not available to existing customers and cannot be combined with any other discount or promotion. The offer is valid from 00:01 05 September 2024 until midnight on 31 December 2024.
Full subscription agreement will outline contractual terms, Customer will be granted optional termination 90 days from “Start Date”. A minimum of 14 days’ notice of termination must be given. This email does not represent contractual obligation. Promotion excludes existing “Track” service customers; customers with an existing signed “Track” subscription agreement. nShift AB standard terms and conditions apply. Promotional offer will run until 30th November 2023. nShift reserves the right to close promotional offer.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240906823045/en/
Contacts
James Ellerington:
James Ellerington:
James.Ellerington@fourteenforty.uk / (+44) 07725 534941
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release
Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom